Primary hyperaldosteronism epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
=== Prevalence === | === Prevalence === | ||
* Worldwide, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) ranges from a low of 10,000 per 100,000 persons with hypertension to a high of 35,000 per 100,000 persons with hypertenion when aldosterone/renin ratio is used as a screening tool.<ref name="pmid17161262">{{cite journal |vauthors=Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F |title=A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients |journal=J. Am. Coll. Cardiol. |volume=48 |issue=11 |pages=2293–300 |year=2006 |pmid=17161262 |doi=10.1016/j.jacc.2006.07.059 |url=}}</ref> | |||
* In patients with resistant hypertension, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) is reported to be even higher, ranging from a low of 17,000 per 100,000 patients to a high of 23,000 per 100,000 patients.<ref name="pmid20498828">{{cite journal |vauthors=Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD |title=Laboratory investigation of primary aldosteronism |journal=Clin Biochem Rev |volume=31 |issue=2 |pages=39–56 |year=2010 |pmid=20498828 |pmc=2874431 |doi= |url= |issn=}}</ref> | |||
=== Incidence === | === Incidence === | ||
Revision as of 15:47, 7 July 2017
Overview
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) ranges from a low of 10,000 per 100,000 persons with hypertension to a high of 35,000 per 100,000 persons with hypertenion when aldosterone/renin ratio is used as a screening tool.[1]
- In patients with resistant hypertension, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) is reported to be even higher, ranging from a low of 17,000 per 100,000 patients to a high of 23,000 per 100,000 patients.[2]
Incidence
Case-Fatality rate
Age
Gender
Race
Geographic Distribution
References
- ↑ Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F (2006). "A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients". J. Am. Coll. Cardiol. 48 (11): 2293–300. doi:10.1016/j.jacc.2006.07.059. PMID 17161262.
- ↑ Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.